Incidence of Cardiovascular Diseases in Patients With Hypopituitarims
Completed
- Conditions
- Cardiovascular Diseases
- Registration Number
- NCT00442858
- Lead Sponsor
- Lund University Hospital
- Brief Summary
The aim of the present study was therefore two-fold: 1) to make a retrospective comparison of incidence of non-fatal stroke and cardiac events between a large cohort of patients with confirmed GHD on replacement therapy (including GH) and a control cohort from the general population; 2) to compare the prevalence of DM and cardioprotective medication between the cohorts at the time of questionnaire distribution with adjustment for possible confounders and effect modifiers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 800
Inclusion Criteria
- Confirmed GH deficiency
Exclusion Criteria
- Not confirmed GH deficiency
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link GH replacement therapy to cardiovascular risk in hypopituitarism patients as studied in NCT00442858?
How does GH therapy in hypopituitarism compare to standard-of-care in preventing non-fatal stroke and cardiac events?
What biomarkers correlate with diabetes mellitus prevalence in hypopituitarism patients versus controls in NCT00442858?
What adverse events are associated with long-term GH replacement in hypopituitarism and how are they managed?
Are there alternative therapies to GH replacement for managing cardiovascular risks in hypopituitarism patients?